| Objective: To observe whether early application of atorvastatin in the acute phase of ischemic stroke can enhance the stability of vulnerable plaque,thereby preventing the progression of stroke,preventing recurrent episodes of ischemic events,and improving ischemic brain.prognosis of stroke patients.At the same time,High-Resolution Magetic Resonance Imaging(HR-MRI)was used to quantitatively and dynamically evaluate atorvastatin-induced lipid-lowering therapy for carotid instability spots by repetitive measurement of plaque volume and composition.The efficacy of the block.Methods: January 2016 to December 2016.There were 150 patients with acute cerebral infarction.A total of 87 patients were enrolled after screening and inclusion criteria.There were 66 males and 21 females with an average age of 63.6±9.4 years.All patients were randomly divided into observation group(group A): the control group was given atorvastatin calcium tablets 20 mg orally or in total for 43 cases.The study group gave 44 cases of atorvastatin calcium tablets 80 mg orally.After 6 months of treatment,the baseline data of the patients were recorded.The wall volume,lumen volume,lipid core volume and lipid core percentage were analyzed by HR-MRI.Blood lipid index,inflammation index hsCRP,design function NIHSS score,liver and kidney index were analyzed.And differences in clinical events.Results: There was no significant difference in the proportion of age,female patient,smoking history,hypertension,hypercholesterolemia,and diabetes between the two groups.At baseline,there were no statistically significant differences in serum lipids including total cholesterol,low-density lipoprotein cholesterol,non-high-density lipoprotein,low-density lipoprotein: high-density lipoprotein,and triglycerides,but at high The difference in density lipoprotein cholesterol was statistically significant(P=0.04).After treatment,the difference between the two groups was statistically significant(all P<0.05)in total cholesterol,low-density lipoprotein cholesterol,non-high-density lipoprotein,and low-density lipoprotein: high-density lipoprotein.There was no significant difference in the two indicators of high-density lipoprotein and triglyceride.At baseline,the hs-CRP levels in the control and intensive treatment groups were 1.7(0.7-3.4)mg/l and 1.7(0.8-3.5)mg/l,respectively,and the difference was not statistically the same,but at the treatment follow-up,control The hsCRP levels in the group and intensive treatment groups were 1.9(0.7-4.7)mg/l and 1.2(0.7-2.5)mg/l,respectively,and the difference was statistically significant.At baseline,there were no significant differences in tube wall volume,lumen volume,mass core volume,and lipid core percentage,but at the post-treatment follow-up,wall volume,lumen volume,core volume,and lipid There were statistically significant differences in the core percentage of the four indicators(all P < 0.05).At baseline,the NIHSS scores for the control and intensive treatment groups were 11.77 ± 1.79 and 11.20 ± 2.64,respectively,and the differences were not statistically similar.At the treatment follow-up,the NIHSS scores for the control and intensive treatment groups were 11.20 ± 2.06 and 10.11,respectively.± 2.14,the difference was statistically significant.At baseline,there was no statistically significant difference in ALT,AST,and CK between the control group and the intensive treatment group.There was no statistically significant difference in ALT,AST,and CK between the follow-up and follow-up treatments.The control group had clinical events such as hemorrhage and creatinine kinase levels >5×ULN and >10×ULN;the number of clinical events in the intensive treatment group was small,and only one creatinine kinase level was >5×ULN,the main adverse events A dose reduction for statins.Conclusions: HR-MRI showed that intensive lipid-lowering therapy can improve plaque,improve neurological function,inflammation level and lipid level,reduce adverse events,and not affect liver and kidney function. |
PDF Full Text Request